A Phase 1b/II Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 15 May 2017
At a glance
- Drugs Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Apr 2017 Status changed from not yet recruiting to recruiting.
- 01 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Sep 2017.